Tuhura Biosciences, Inc./Nv (HURA) Stock Price & Analysis
Tuhura Biosciences, Inc./Nv (HURA) rose 2.97% to USD 2.08 as of June 11, 2026 at 04:13 UTC, according to Nexqual real-time market data.
HURA last closed at USD 2.02; the session ranged USD 2.01–2.11 on volume of 412,023 shares. Market capitalization is $132.46M, with a 52-week range of USD 0.41–3.9 (NCM). Source: Nexqual, June 11, 2026 at 04:13 UTC.
Key Statistics (as of June 11, 2026 at 04:13 UTC)
| Price | USD 2.08 |
|---|---|
| Change | ▲ 2.97% (up) |
| Previous Close | USD 2.02 |
| Open | USD 2.01 |
| Day Range | USD 2.01 – 2.11 |
| 52-Week Range | USD 0.41 – 3.9 |
| Volume | 412,023 shares |
| Market Cap | $132.46M |
| Exchange | NCM |
Technical Analysis (HURA)
Nexqual's technical model rates HURA "SELL" based on 1 bullish and 5 bearish signals across 123 daily candles, as of June 11, 2026 at 04:13 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 36.75 (neutral) |
| vs SMA50 | Below (USD 2.3) |
| MACD | -0.08 (negative) |
Analyst Ratings (HURA)
Wall Street analysts rate HURA "Strong Buy" based on 5 analysts, with a mean price target of USD 8.04 (range USD 6.2–10), per Nexqual as of June 11, 2026 at 04:13 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 8.04 |
| High Target | USD 10 |
| Low Target | USD 6.2 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (HURA)
| Next Earnings Date | 2026-08-13 |
|---|---|
| EPS Estimate | USD -0.12 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.13 vs est -0.11 ▼ miss |
| 2025-12-31 | USD -0.16 vs est -0.12 ▼ miss |
| 2025-09-30 | USD -0.14 vs est -0.15 ▲ beat |
| 2025-06-30 | USD -0.21 vs est -0.14 ▼ miss |
Source: Nexqual, June 11, 2026 at 04:13 UTC.
Financials & Fundamentals (HURA)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -187.16% |
| Debt / Equity | 1.97 |
| Current Ratio | 1.15 |
| Total Cash | $6.30M |
| Total Debt | $456,926 |
| Free Cash Flow | $-1.62M |
Source: Nexqual, June 11, 2026 at 04:13 UTC.
Financial Health Score (HURA)
Nexqual rates Tuhura Biosciences, Inc./Nv's overall financial health "Weak" across five dimensions, as of June 11, 2026 at 04:13 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $6M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$27M |
| Efficiency | Critical — ROE -187%, ROA -81.9% |
Ownership (HURA)
| Insider Ownership | +34.65% |
|---|---|
| Institutional Ownership | +14.97% |
| Shares Outstanding | 63.68M |
| Float | 35.59M |
| Short % of Float | +17.19% |
Source: Nexqual, June 11, 2026 at 04:13 UTC.
Leadership (HURA)
Tuhura Biosciences, Inc./Nv is led by James A. Bianco (age 68), President, CEO & Director, per Nexqual as of June 11, 2026 at 04:13 UTC.
| President, CEO & Director | James A. Bianco (age 68) |
|---|---|
| Executive VP of Finance & CFO | Dan Dearborn (age 57) |
| Senior Vice President of Clinical Operations | Amanda Garofalo |
Major Backers & Investors (HURA)
Notable institutional backers of Tuhura Biosciences, Inc./Nv include Fidelity, AQR Capital Management, LLC, Apollon Wealth Management, LLC, according to Nexqual as of June 11, 2026 at 04:13 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 0.97% |
| AQR Capital Management, LLC | 0.95% |
| Apollon Wealth Management, LLC | 0.25% |
| Charles Schwab | 0.13% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 7.57% |
| BlackRock | 6.03% |
| Geode Capital | 1.55% |
| State Street | 0.81% |
| Northern Trust | 0.47% |
| BNY Mellon | 0.33% |
Source: Nexqual, June 11, 2026 at 04:13 UTC.
From Tuhura Biosciences, Inc./Nv's Latest SEC 10-K Filing (filed 2026-03-31)
Key Strengths & Strategy (as disclosed to the SEC)
- Our proprietary Immune FxTM technology platform, or IFx, is an innate immune agonist technology designed to "trick" the body's immune system to attack tumor cells by making tumor cells look like bacteria.
- We believe we are the first company developing immune modulating ADCs targeting the Delta Opioid Receptor on MDSCs.
- To our knowledge we are the only company developing ADCs targeting MDSCs where our ADCs are designed to be bi-specific/ bi-functional, i.e. , affecting two targets and having two functions: inhibiting tumor associated MDSC-related immune suppression and thereby making tumor susceptible to attack, while localizing checkpoint inhibitors where the tumor resides.
- IFx Innate Immune Agonist Development Program We have developed Immune Fx TM , or IFx, as an innate immune agonist technology designed to "trick" the body's immune system to attack tumor cells by making tumor cells look like bacteria and to thereby harness the natural power of innate immunity by leveraging natural mechanisms conserved throughout evolution to recognize threats from foreign pathogens like bacteria or viruses.
Partnerships
- He also led CTI Biopharma in the negotiation of the development and commercial license agreement with Baxalta.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TCMD | Tactile Systems Technology, Inc | USD 25.97 | ▲ 2.85% |
| SXTP | 60 Degrees Pharmaceuticals, Inc | USD 1.38 | ▼ 3.5% |
| DTCX | Datacentrex, Inc. | USD 2.12 | ▼ 2.3% |
| QNCX | Quince Therapeutics, Inc. | USD 0.91 | ▼ 9% |
| KAPA | Kairos Pharma, Ltd. | USD 0.43 | ▼ 4.44% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 11, 2026 at 04:13 UTC. This page is informational and not investment advice.